• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Bionano Genomics Inc.

    3/25/26 4:28:43 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BNGO alert in real time by email
    S-8 1 bngo-20260325.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 25, 2026

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    Bionano Genomics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    26-1756290

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

     

     

     

    9540 Towne Centre Drive, Suite 100

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

    Bionano Genomics, Inc. Amended and Restated 2018 Equity Incentive Plan, as amended

    Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan

    (Full titles of the plans)

    R. Erik Holmlin, Ph.D.

    President and Chief Executive Officer

    Bionano Genomics, Inc.

    9540 Towne Centre Drive, Suite 100

    San Diego, California 92121

    (858) 888-7600

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    Rakesh Gopalan

    David S. Wolpa

    Troutman Pepper Locke LLP

    301 S. College Street, Suite 3400

    Charlotte, NC 28202

    (704) 998-4050

     

     

    R. Erik Holmlin, Ph.D.

    President and Chief Executive Officer

    Bionano Genomics, Inc.

    9540 Towne Centre Drive, Suite 100

    San Diego, California 92121

    (858) 888-7600

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☐

     

     

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed by Bionano Genomics, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “SEC”) for the purpose of registering (i) an additional 537,009 shares of Registrant’s Common Stock, par value $0.0001 per share (“Common Stock”), issuable under the Registrant’s 2018 Equity Incentive Plan, as amended (the “2018 Plan”), pursuant to the provisions of the 2018 Plan providing for an automatic increase on January 1 of each year in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan and (ii) an additional 366 shares of Common Stock issuable under the Registrant’s 2018 Employee Stock Purchase Plan (the “2018 ESPP”) pursuant to the provisions of the 2018 ESPP providing for an automatic increase on January 1 of each year in the number of shares of Common Stock reserved and available for issuance under the 2018 ESPP. In accordance with the instructional note to Part I of Form S-8 as promulgated by the SEC, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    These additional shares of Common Stock are securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the 2018 Plan and the 2018 ESPP is effective. The Registrant previously registered shares of its Common Stock for issuance under the 2018 Plan and the 2018 ESPP under Registration Statements on Form S-8 as noted below.

     

    The following documents filed by the Registrant with the SEC are incorporated by reference into this Registration Statement:

     

    (a)
    The contents of the earlier registration statements on Form S-8 pertaining to the 2018 Plan and 2018 ESPP filed with the SEC on August 28, 2018 (File No. 333-227073), March 29, 2019 (File No. 333-230589), March 11, 2020 (File No. 333-237069), August 14, 2020 (File No. 333-245764), March 24, 2021 (File No. 333-254654), March 1, 2022 (File No. 333-263176), March 9, 2023 (File No. 333-270430), May 8, 2024 (File No. 333-279229), and April 2, 2025 (File No. 333-286325);

     

    (b)
    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, which included audited financial statements for the Registrant’s latest fiscal year, filed with the SEC on March 23, 2026; and

     

    (c)
    The description of the Registrant’s Common Stock contained in a registration statement on Form 8-A filed with the SEC on July 31, 2018 (File No. 001-38613) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description including Exhibit 4.5 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 5, 2024.

     

    All reports and other documents subsequently filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports or portions thereof furnished under Item 2.02 or Item 7.01 or any related Item 9.01 of Form 8-K and exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the SEC, after the date of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities offered hereby then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or


    supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this registration statement, except as so modified or superseded.

     

    Item 8. Exhibits.

     

    Exhibit

    Number

     

    Description

    4.1(1)

     

    Amended and Restated Certificate of Incorporation of the Registrant, as amended.

    4.2(2)

     

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended.

    4.3(3)

     

    Amended and Restated Bylaws of the Registrant.

    4.4(4)

     

    Amendment to Amended and Restated Bylaws.

    4.5(5)

     

    Form of Common Stock Certificate of the Registrant.

    5.1*

     

    Opinion of Troutman Pepper Locke LLP.

    23.1*

     

    Consent of BDO USA LLP, Independent Registered Public Accounting Firm.

    23.2*

     

    Consent of Troutman Pepper Locke LLP (included as part of Exhibit 5.1).

    24.1

     

    Power of Attorney (included in the signature page to this registration statement).

    99.1(6)

     

    Bionano Genomics, Inc. 2018 Equity Incentive Plan, as amended.

    99.2(7)

     

    Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan.

    107*

     

    Filing Fee Table.

     

     

    (1)

    Incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on November 8, 2023.

    (2)

    Incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K, filed with the SEC on January 27, 2025.

    (3)

    Incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K, filed with the SEC on August 24, 2018.

    (4)

    Incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K, filed with the SEC on April 14, 2023.

    (5)

    Incorporated by reference to Exhibit 4.1 of the Registrant’s Statement on Form S-1 (File No. 333-225970), as amended, originally filed with the SEC on June 28, 2018).

    (6)

    Incorporated by reference to Exhibit 99.1 of the Registrant’s Registration Statement on Form S-8 (File No. 333-245764), filed with the SEC on August 13, 2020.

    (7)

    Incorporated by reference to Exhibit 99.5 of the Registrant’s Registration Statement on Form S-8 (File No. 333-227073), filed with the SEC on August 28, 2018.

    *

    Filed herewith.

     


    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 25, 2026.

     

    BIONANO GENOMICS, INC.

     

     

     

     

     

    By:

    /s/ R. Erik Holmlin, Ph.D.

     

     

    R. Erik Holmlin, Ph.D.

     

     

    President and Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of R. Erik Holmlin, Ph.D. and Mark Adamchak as their true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ R. Erik Holmlin, Ph.D.

     

    President, Chief Executive Officer and Director
    (Principal Executive Officer and Principal Financial Officer)

     

    March 25, 2026

    R. Erik Holmlin, Ph.D.

     

     

     

     

     

     

     

     

    /s/ Mark Adamchak

     

    VP, Accounting
    (Principal Accounting Officer)

     

    March 25, 2026

    Mark Adamchak

     

     

     

     

     

     

     

     

    /s/ David L. Barker, Ph.D.

     

    Director

     

    March 25, 2026

    David L. Barker, Ph.D.

     

     

     

     

     

     

     

     

    /s/ Yvonne Linney, Ph.D.

     

    Director

     

    March 25, 2026

    Yvonne Linney, Ph.D.

     

     

     

     

     

     

     

     

    /s/ Albert A. Luderer, Ph.D.

     

    Director

     

    March 25, 2026

    Albert A. Luderer, Ph.D.

     

     

     

     

     

     

     

     

    /s/ Hannah Mamuszka

     

    Director

     

    March 25, 2026


    Hannah Mamuszka

     

     

     

     

     

     

     

     

     

    /s/ Aleksandar Rajkovic, M.D., Ph.D.

     

    Director

     

    March 25, 2026

    Aleksandar Rajkovic, M.D., Ph.D.

     

     

     

     

     

     

     

     

    /s/ Christopher Twomey

     

    Director

     

    March 25, 2026

    Christopher Twomey

     

     

     

     

     

     

     

     

    /s/ Kristiina Vuori, M.D., Ph.D.

     

    Director

     

    March 25, 2026

    Kristiina Vuori, M.D., Ph.D.

     

     

     

     

     

     

     

     


    Get the next $BNGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNGO

    DatePrice TargetRatingAnalyst
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    9/10/2024Buy → Neutral
    BTIG Research
    1/5/2023$4.00Sector Outperform
    Scotiabank
    12/12/2022$3.50Buy
    BTIG Research
    7/18/2022$12.00Outperform
    Oppenheimer
    More analyst ratings

    $BNGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Chaubey Alka covered exercise/tax liability with 18 shares, decreasing direct ownership by 3% to 644 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:31:45 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 3 shares, decreasing direct ownership by 1% to 260 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:29:36 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 6 shares, decreasing direct ownership by 2% to 263 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:28:24 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026

    SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business," commented Erik Holmlin, PhD, president and CEO of Bionano. "Our routine users of optical genome mapping (OGM) and VIA™ software remain the foundation of our revenue and gross margins, and we are pleased to see continued growth in utilization among this core customer base. The global OGM community continues to show extraordinary energy, from the record attendance and engagement at the Bionano Symposium 2026 – where leading laboratories described scaling OGM w

    3/23/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

    SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ:BNGO) participated in the 2026 American College of Medical Genetics and Genomics Annual Meeting (ACMG), held March 14–18 in Baltimore, Maryland. Twelve studies, representing a two-fold increase over the number of studies in 2025, were presented as either oral (4) or poster presentations (8). The studies illustrated how optical genome mapping (OGM) can drive discoveries in genomics by detecting structural variants (SVs) that may be missed by other techniques across cancer genomics, such as hematologic malignancies, and constitutional genetic disorders, including rare diseases and reproductive disorders. Additionally, the

    3/17/26 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.biona

    3/9/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    SEC Filings

    View All

    SEC Form S-8 filed by Bionano Genomics Inc.

    S-8 - Bionano Genomics, Inc. (0001411690) (Filer)

    3/25/26 4:28:43 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-K filed by Bionano Genomics Inc.

    10-K - Bionano Genomics, Inc. (0001411690) (Filer)

    3/23/26 4:08:58 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bionano Genomics, Inc. (0001411690) (Filer)

    3/23/26 4:04:52 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bionano Genomics downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral

    11/15/24 7:40:01 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics downgraded by BTIG Research

    BTIG Research downgraded Bionano Genomics from Buy to Neutral

    9/10/24 7:37:53 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on Bionano Genomics with a new price target

    Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00

    1/5/23 7:29:54 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    2/13/24 5:00:51 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    7/7/23 4:35:55 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    1/30/23 4:03:23 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Financials

    Live finance-specific insights

    View All

    Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026

    SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business," commented Erik Holmlin, PhD, president and CEO of Bionano. "Our routine users of optical genome mapping (OGM) and VIA™ software remain the foundation of our revenue and gross margins, and we are pleased to see continued growth in utilization among this core customer base. The global OGM community continues to show extraordinary energy, from the record attendance and engagement at the Bionano Symposium 2026 – where leading laboratories described scaling OGM w

    3/23/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.biona

    3/9/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025

    SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, November 13th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/4jh5a49o Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at htt

    10/30/25 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Leadership Updates

    Live Leadership Updates

    View All

    Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale

    SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping (OGM), including processing up to thousands of samples per year with automation, multiple OGM systems, and VIA™ software. Other talks covered topics like Bionano's Ionic® system for isolating DNA and RNA for next generation sequencing (NGS) and advanced analytical tools that could be the future of digital cytogenetics

    2/27/26 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    LeddarTech Appoints Chris Stewart as Chief Financial Officer

    QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial

    11/15/23 12:07:00 AM ET
    $BNGO
    $PRSR
    $TSLA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Blank Checks
    Finance

    Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

    SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe

    8/14/23 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials